Persistent SARS-CoV-2 Infection in a Patient with Nephrotic Syndrome under Rituximab Therapy: Successful Treatment with a Combination of Remdesivir and Monoclonal Antibodies

Rituximab is an effective treatment for frequently relapsing/steroid-dependent nephrotic syndrome, but there is concern about infections caused by humoral immunodeficiency. We herein report a case of prolonged (＞7 weeks) severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection. A 24-ye...

Descripción completa

Detalles Bibliográficos
Autores principales: Shimizu, Akihiro, Shirai, Izumi, Ogawa, Kyohei, Miura, Akane, Haruhara, Kotaro, Oshiro, Kentaro, Hamaguchi, Akihiko, Yokote, Shinya, Okabe, Masahiro, Ueda, Hiroyuki, Tsuboi, Nobuo, Ikeda, Masato, Yokoo, Takashi
Formato: Online Artículo Texto
Lenguaje:English
Publicado: The Japanese Society of Internal Medicine 2022
Materias:
Case Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9841105/
https://www.ncbi.nlm.nih.gov/pubmed/36171121
http://dx.doi.org/10.2169/internalmedicine.0241-22
_version_ 1784869758879924224
author Shimizu, Akihiro
Shirai, Izumi
Ogawa, Kyohei
Miura, Akane
Haruhara, Kotaro
Oshiro, Kentaro
Hamaguchi, Akihiko
Yokote, Shinya
Okabe, Masahiro
Ueda, Hiroyuki
Tsuboi, Nobuo
Ikeda, Masato
Yokoo, Takashi
author_facet Shimizu, Akihiro
Shirai, Izumi
Ogawa, Kyohei
Miura, Akane
Haruhara, Kotaro
Oshiro, Kentaro
Hamaguchi, Akihiko
Yokote, Shinya
Okabe, Masahiro
Ueda, Hiroyuki
Tsuboi, Nobuo
Ikeda, Masato
Yokoo, Takashi
author_sort Shimizu, Akihiro
collection PubMed
description Rituximab is an effective treatment for frequently relapsing/steroid-dependent nephrotic syndrome, but there is concern about infections caused by humoral immunodeficiency. We herein report a case of prolonged (＞7 weeks) severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection. A 24-year-old man with minimal change disease treated with rituximab developed SARS-CoV-2 infection. The clinical response to remdesivir was soon transiently abolished. Treatment with casirivimab and imdevimab (REGEN-COV) monoclonal antibodies in combination with remdesivir resulted in complete clearance of the infection. The REGEN-COV antibody cocktail may improve the outcome of SARS-CoV-2 infection in patients with humoral immunodeficiency.
format Online
Article
Text
id pubmed-9841105
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher The Japanese Society of Internal Medicine
record_format MEDLINE/PubMed
spelling pubmed-98411052023-01-26 Persistent SARS-CoV-2 Infection in a Patient with Nephrotic Syndrome under Rituximab Therapy: Successful Treatment with a Combination of Remdesivir and Monoclonal Antibodies Shimizu, Akihiro Shirai, Izumi Ogawa, Kyohei Miura, Akane Haruhara, Kotaro Oshiro, Kentaro Hamaguchi, Akihiko Yokote, Shinya Okabe, Masahiro Ueda, Hiroyuki Tsuboi, Nobuo Ikeda, Masato Yokoo, Takashi Intern Med Case Report Rituximab is an effective treatment for frequently relapsing/steroid-dependent nephrotic syndrome, but there is concern about infections caused by humoral immunodeficiency. We herein report a case of prolonged (＞7 weeks) severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection. A 24-year-old man with minimal change disease treated with rituximab developed SARS-CoV-2 infection. The clinical response to remdesivir was soon transiently abolished. Treatment with casirivimab and imdevimab (REGEN-COV) monoclonal antibodies in combination with remdesivir resulted in complete clearance of the infection. The REGEN-COV antibody cocktail may improve the outcome of SARS-CoV-2 infection in patients with humoral immunodeficiency. The Japanese Society of Internal Medicine 2022-09-28 2022-12-15 /pmc/articles/PMC9841105/ /pubmed/36171121 http://dx.doi.org/10.2169/internalmedicine.0241-22 Text en Copyright © 2022 by The Japanese Society of Internal Medicine https://creativecommons.org/licenses/by-nc-nd/4.0/The Internal Medicine is an Open Access journal distributed under the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License. To view the details of this license, please visit (https://creativecommons.org/licenses/by-nc-nd/4.0/).
spellingShingle Case Report
Shimizu, Akihiro
Shirai, Izumi
Ogawa, Kyohei
Miura, Akane
Haruhara, Kotaro
Oshiro, Kentaro
Hamaguchi, Akihiko
Yokote, Shinya
Okabe, Masahiro
Ueda, Hiroyuki
Tsuboi, Nobuo
Ikeda, Masato
Yokoo, Takashi
Persistent SARS-CoV-2 Infection in a Patient with Nephrotic Syndrome under Rituximab Therapy: Successful Treatment with a Combination of Remdesivir and Monoclonal Antibodies
title Persistent SARS-CoV-2 Infection in a Patient with Nephrotic Syndrome under Rituximab Therapy: Successful Treatment with a Combination of Remdesivir and Monoclonal Antibodies
title_full Persistent SARS-CoV-2 Infection in a Patient with Nephrotic Syndrome under Rituximab Therapy: Successful Treatment with a Combination of Remdesivir and Monoclonal Antibodies
title_fullStr Persistent SARS-CoV-2 Infection in a Patient with Nephrotic Syndrome under Rituximab Therapy: Successful Treatment with a Combination of Remdesivir and Monoclonal Antibodies
title_full_unstemmed Persistent SARS-CoV-2 Infection in a Patient with Nephrotic Syndrome under Rituximab Therapy: Successful Treatment with a Combination of Remdesivir and Monoclonal Antibodies
title_short Persistent SARS-CoV-2 Infection in a Patient with Nephrotic Syndrome under Rituximab Therapy: Successful Treatment with a Combination of Remdesivir and Monoclonal Antibodies
title_sort persistent sars-cov-2 infection in a patient with nephrotic syndrome under rituximab therapy: successful treatment with a combination of remdesivir and monoclonal antibodies
topic Case Report
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9841105/
https://www.ncbi.nlm.nih.gov/pubmed/36171121
http://dx.doi.org/10.2169/internalmedicine.0241-22
work_keys_str_mv AT shimizuakihiro persistentsarscov2infectioninapatientwithnephroticsyndromeunderrituximabtherapysuccessfultreatmentwithacombinationofremdesivirandmonoclonalantibodies
AT shiraiizumi persistentsarscov2infectioninapatientwithnephroticsyndromeunderrituximabtherapysuccessfultreatmentwithacombinationofremdesivirandmonoclonalantibodies
AT ogawakyohei persistentsarscov2infectioninapatientwithnephroticsyndromeunderrituximabtherapysuccessfultreatmentwithacombinationofremdesivirandmonoclonalantibodies
AT miuraakane persistentsarscov2infectioninapatientwithnephroticsyndromeunderrituximabtherapysuccessfultreatmentwithacombinationofremdesivirandmonoclonalantibodies
AT haruharakotaro persistentsarscov2infectioninapatientwithnephroticsyndromeunderrituximabtherapysuccessfultreatmentwithacombinationofremdesivirandmonoclonalantibodies
AT oshirokentaro persistentsarscov2infectioninapatientwithnephroticsyndromeunderrituximabtherapysuccessfultreatmentwithacombinationofremdesivirandmonoclonalantibodies
AT hamaguchiakihiko persistentsarscov2infectioninapatientwithnephroticsyndromeunderrituximabtherapysuccessfultreatmentwithacombinationofremdesivirandmonoclonalantibodies
AT yokoteshinya persistentsarscov2infectioninapatientwithnephroticsyndromeunderrituximabtherapysuccessfultreatmentwithacombinationofremdesivirandmonoclonalantibodies
AT okabemasahiro persistentsarscov2infectioninapatientwithnephroticsyndromeunderrituximabtherapysuccessfultreatmentwithacombinationofremdesivirandmonoclonalantibodies
AT uedahiroyuki persistentsarscov2infectioninapatientwithnephroticsyndromeunderrituximabtherapysuccessfultreatmentwithacombinationofremdesivirandmonoclonalantibodies
AT tsuboinobuo persistentsarscov2infectioninapatientwithnephroticsyndromeunderrituximabtherapysuccessfultreatmentwithacombinationofremdesivirandmonoclonalantibodies
AT ikedamasato persistentsarscov2infectioninapatientwithnephroticsyndromeunderrituximabtherapysuccessfultreatmentwithacombinationofremdesivirandmonoclonalantibodies
AT yokootakashi persistentsarscov2infectioninapatientwithnephroticsyndromeunderrituximabtherapysuccessfultreatmentwithacombinationofremdesivirandmonoclonalantibodies

Ejemplares similares